Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cancer Cells Look for a Soft Bed

By Drug Discovery Trends Editor | August 6, 2014

Cancer cells that break away from tumors to go looking for a new home may prefer to settle into a soft bed, according to new findings from researchers at the University of Illinois.
 
Some particularly enterprising cancer cells can cause a cancer to spread to other organs, called metastasis, or evade treatment to resurface after a patient is thought to be in remission. The Illinois team, along with colleagues in China, found that these so-called tumor-repopulating cells may lurk quietly in stiffer cellular environments, but thrive in a softer space. The results appear in the journal Nature Communications.
 
“What causes relapse is not clear,” said study leader Ning Wang. Wang is the Leonard C. and Mary Lou Hoeft Professor in Engineering and professor of mechanical science and engineering of the U. of I. “Why are there a few cells left that can come back stronger? We thought cancer cells may have some properties in common with stem cells, which allows them to metastasize to different tissues. Normally, if you take a liver cell and put it in your lung, it will die. But an undifferentiated cell will live.”
 
Two years ago, Wang’s group published a method for selecting tumor-repopulating cells (TRCs) from a culture. Thanks to this selection method, the researchers isolated and studied TRCs from melanoma, an aggressive skin cancer notorious for spreading and recurring, to see how the mechanical environment around the cells affected their ability to multiply and cause new tumors.
 
The researchers grew the cells on gels of different stiffnesses – some very soft and some more firm, to mimic different types of tissues in the body. What they found surprised them.
 
The TRCs placed in very soft gels grew and multiplied, as expected. The cells placed on stiffer gels did not proliferate; however, they did not die, either – they became dormant. When the researchers later transferred the dormant TRCs to a soft gel, the cells “woke up” and began to multiply and spread.
 
Wang speculates that these properties of dormancy and reawakening when the mechanical environment is more inviting may explain why soft tissues, such as the brain or lungs, are most vulnerable to metastasis.
 
“We have many different types of organs where solid tumors originate, but if you look at the metastasized sites, the majority are in soft tissues,” said Wang. “Brain, lung, liver and bone marrow, all soft. So it may not be coincidence. We need to do more research.”
 
Next, Wang and colleagues hope to tackle the question of what makes TRCs so resistant to drugs, a trait that makes recurrent cancer much harder to treat. Unlocking this puzzle may help doctors fight recurrent cancer, although Wang hopes that understanding how TRCs work can lead to treatments that prevent metastasis in the first place.
 
“The key issue in this paper is outlining the mechanisms that control how TRCs proliferate,” Wang said. “The importance of knowing these mechanisms is that we now have targets that we didn’t have before, specific targets for new types of drugs that will interfere with this renewal pathway. It could give us a new avenue for treatment and preventing relapse.”
 
Date: August 6, 2014
Source: University of Illinois

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE